BR0014667A - Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea - Google Patents

Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea

Info

Publication number
BR0014667A
BR0014667A BR0014667-6A BR0014667A BR0014667A BR 0014667 A BR0014667 A BR 0014667A BR 0014667 A BR0014667 A BR 0014667A BR 0014667 A BR0014667 A BR 0014667A
Authority
BR
Brazil
Prior art keywords
diseases
hypercoagulable state
tissue factor
prevention
human tissue
Prior art date
Application number
BR0014667-6A
Other languages
English (en)
Inventor
Hiroyuki Saito
Takehisa Kitazawa
Kazutaka Yoshihashi
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR0014667A publication Critical patent/BR0014667A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ecology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

Patente de Invenção: "PREVENçãO E TRATAMENTO DE DOENçAS RELACIONADAS à COAGULAçãO SANGuìNEA". é fornecido um animal tendo um estado hipercoagulável persistente enxertando uma célula, por exemplo, uma célula tumoral, em que o gene de fator de tecido humano é inserido em um animal experimental tal como um camundongo e depois desenvolvendo a dita célula, dessa forma persistentemente fornecendo o fator de tecido humano ao dito animal experimental. Este modelo animal é útil para pesquisa e desenvolvimento dos agentes terapêuticos para doenças tendo um estado hipercoagulável persistente. A presente invenção também fornece agentes preventivos ou terapêuticos para doenças tendo um estado hipercoagulável persistente, um estado hipercoagulável resultante de infecções, trombose venosa, trombose arterial e doenças resultantes da hipertrofia de meios vasculares, o dito agente compreendendo um anticorpo contra o fator de tecido humano (TF humano) como um ingrediente ativo.
BR0014667-6A 1999-10-01 2000-09-29 Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea BR0014667A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP28216799 1999-10-01
JP28184399 1999-10-01
JP28212099 1999-10-01
JP28219299 1999-10-01
JP28213499 1999-10-01
JP28218899 1999-10-01
PCT/JP2000/006802 WO2001024626A1 (fr) 1999-10-01 2000-09-29 Prevention et traitement de maladies associees a la coagulation sanguine

Publications (1)

Publication Number Publication Date
BR0014667A true BR0014667A (pt) 2002-07-02

Family

ID=27554423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014667-6A BR0014667A (pt) 1999-10-01 2000-09-29 Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea

Country Status (18)

Country Link
US (2) US8062638B1 (pt)
EP (2) EP2351483A1 (pt)
JP (1) JP3859512B2 (pt)
KR (1) KR20030008205A (pt)
AT (1) ATE498305T1 (pt)
AU (1) AU7450600A (pt)
BR (1) BR0014667A (pt)
CA (1) CA2388408A1 (pt)
CZ (1) CZ20021035A3 (pt)
DE (1) DE60045638D1 (pt)
DK (1) DK1222854T3 (pt)
HU (1) HUP0203486A2 (pt)
IL (1) IL148980A0 (pt)
MX (1) MXPA02003278A (pt)
NO (1) NO20021410L (pt)
PL (1) PL354961A1 (pt)
SK (1) SK4442002A3 (pt)
WO (1) WO2001024626A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JPWO2002078738A1 (ja) * 2001-03-26 2004-10-07 鈴木　宏治 血液レオロジー改善剤
US7592502B2 (en) 2001-05-18 2009-09-22 Chugai Seiyaku Kabushiki Kaisha Knock-in non-human animal producing human tissue factor
PL368989A1 (en) * 2001-10-02 2005-04-04 Novo Nordisk A/S Human tissue factor antibodies
EP1550455A1 (en) * 2002-05-23 2005-07-06 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
JP4607010B2 (ja) * 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
AU1948388A (en) * 1987-06-12 1989-01-04 Mount Sinai School Of Medicine Of The City University Of New York, The Cloning and expression of human tissue factor
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
DE69229482T2 (de) 1991-04-25 1999-11-18 Chugai Seiyaku K.K., Tokio/Tokyo Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
US5346991A (en) 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
JP3865418B2 (ja) 1994-07-13 2007-01-10 中外製薬株式会社 ヒトインターロイキン−８に対する再構成ヒト抗体
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
RU2198220C2 (ru) 1996-09-26 2003-02-10 Чугаи Сейяку Кабусики Кайся Антитело против белка, родственного паращитовидному гормону человека, днк, вектор, способ получения и использование антитела
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DK1069185T3 (da) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
IL148980A0 (en) 2002-11-10
NO20021410L (no) 2002-05-24
CZ20021035A3 (cs) 2002-08-14
JP3859512B2 (ja) 2006-12-20
HUP0203486A2 (hu) 2003-02-28
WO2001024626A1 (fr) 2001-04-12
SK4442002A3 (en) 2003-04-01
DE60045638D1 (de) 2011-03-31
EP1222854A1 (en) 2002-07-17
MXPA02003278A (es) 2002-09-02
EP1222854B1 (en) 2011-02-16
EP1222854A4 (en) 2006-07-05
NO20021410D0 (no) 2002-03-21
US8062638B1 (en) 2011-11-22
PL354961A1 (en) 2004-03-22
AU7450600A (en) 2001-05-10
EP2351483A1 (en) 2011-08-03
ATE498305T1 (de) 2011-03-15
KR20030008205A (ko) 2003-01-24
US20120073002A1 (en) 2012-03-22
CA2388408A1 (en) 2001-04-12
DK1222854T3 (da) 2011-03-14

Similar Documents

Publication Publication Date Title
Jeroukhimov et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
CZ259897A3 (cs) Použití plynného oxidu dusnatého pro přípravu léčiva pro léčení, inhibici nebo prevenci vaskulární trombózy nebo arteriální restenózy
BRPI0410419A (pt) tratamento para a ansiedade com ziprasidona
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DE60213404D1 (de) Verwendung von sulodexid zur behandlung von reizdarm
JPH0813742B2 (ja) 血液凝固阻止剤
US10117842B2 (en) Methods and materials for reducing ischemia-reperfusion injury
BR0014667A (pt) Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DK0730460T3 (da) Anvendelsen af en ester af inositoltriphosphat til behandlingen af betændelsestilstande
Gloviczki et al. The natural history of microsurgical lymphovenous anastomoses: an experimental study
BR9914834A (pt) Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese
Xu et al. The effects of the duration of aortic balloon occlusion on outcomes of traumatic cardiac arrest in a porcine model
Lapin et al. Vascular catheterization in small laboratory animals in biomedical research: technological aspects of the method
BR0012661A (pt) Métodos de tratamento e métodos de triagem de drogas
Ferancikova et al. Bromelain-based enzymatic debridement as a treatment of choice in high-risk patient with deep facial burns, a case report
Shimamura et al. A model of rat embolic cerebral infarction with a quantifiable, autologous arterial blood clot
Haga et al. Treatment of prosthetic vascular graft infection in the groin with ultrasound debridement: A case report
Hamad et al. Stem Cells and Nanosilver Saved Diabetic Foot
Buckberg Stroke and extra-cardiac perfusion: new vantage points in brain protection
Peacock Jr Future trends in wound healing research
Qi et al. Development of a local vasodilator delivery system using fibrin glue to prevent arterial graft from spasm
Storm et al. Acute deep vein thrombosis treated with porcine plasmin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.